A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa

Completed · Phase 4 · Has a placebo group

Conditions studied: Anorexia Nervosa

In brief

The aim of this pilot study is to determine the safety and efficacy of risperidone for the treatment of anorexia nervosa. Hypothesis 1: Subjects on risperidone will show a more significant decrease in body image distortion and Eating Disorder Inventory -2 scores than subjects on placebo. Hypothesis 2: Subjects on risperidone will reach and maintain at or above 90% Ideal body weight sooner than controls.

Key facts

Study ID
NCT00140426
Run by
University of Colorado, Denver
People needed
41
Starts
2004-08-01
Expected to finish
2009-12-01
Last updated by the study team
2016-02-02

Who can join

Age: 12 and older, up to 21. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.